Aenova and Haupt Pharma To Merge

The Aenova Group, a provider of development and manufacturing services for medicines and dietary supplements reported it will merge with Haupt Pharma, a company specializing in contract development and manufacturing. An agreement has been signed, but the purchase price remains confidential. The transaction will proceed subject to the approval of the relevant competition authorities, but is expected to become legally binding at the end of 2013.

The merger will add areas such as sterile manufacturing and the production of special active ingredients (including hormones, antibiotics, and cytostatics) to Aenova.

Aenova’s network will increase from eight to 21 sites including production facilities in Germany (Berlin, Brackenheim, Münster, Gronau, Regensburg, Wolfratshausen) and in Europe, its first site in Japan. The number of employees will increase from 2,500 to more than 4,000.

Source: Aenova Group